文献速递药物相互作用治疗药物监测与药物基因组学

从内源性生物标志物到血浆来源纳米囊泡液体活检:转化药代动力学-ADME-DDI科学的黄金时代是否已经到来?

From Endogenous Compounds as Biomarkers to Plasma-Derived Nanovesicles as Liquid Biopsy; Has the Golden Age of Translational Pharmacokinetics-Absorption, Distribution, Metabolism, Excretion-Drug-Drug Interaction Science Finally Arrived?
PubMed 文献 · Clin Pharmacol Ther · 2019-02-12

本文综述了内源性化合物作为药物代谢酶和转运体生物标志物在受试者表型分析和临床DDI评估中的应用,并指出循环细胞外囊泡作为液体活检在ADME领域关注较少。血浆外泌体携带来源器官的蛋白质、mRNA和miRNA,其ADME分析可用于定义基因型-表型关系及研究个体发育、疾病和复杂DDI。若组织来源血浆外泌体分离方法得以开发验证,有望与基因分型、生物标志物和建模工具联合推进转化PK-ADME-DDI科学。

要点

  • 内源性化合物已用于药物代谢酶和转运体生物标志物以促进表型分析和DDI评估。
  • 血浆外泌体携带来源器官的货物分子,可作为液体活检用于ADME表型分析。
  • 外泌体分离方法的开发验证是将其用于转化PK-ADME-DDI研究的关键前提。

核心结论

  • 血浆来源纳米囊泡作为液体活检有望与基因分型、生物标志物和建模工具联合,推进转化PK-ADME-DDI科学。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • 药物PK/ADME/DDI特征受年龄、疾病和基因型调控。
  • 内源性化合物(血浆和尿液中)已被 pursued 作为药物代谢酶和转运体生物标志物。
  • 循环细胞外囊泡作为液体活检在ADME领域关注较少;多数器官向血液分泌含蛋白质、mRNA和miRNA的纳米囊泡。
  • 血浆外泌体的ADME分析可用于定义基因型-表型关系及研究个体发育、疾病和复杂DDI。

临床怎么用

  • 若组织来源血浆外泌体分离方法开发验证成功,可联合基因分型、生物标志物和建模工具用于转化PK-ADME-DDI研究。

局限性

  • 支持组织来源血浆外泌体分离的方法尚未成功开发验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is now established that a drug's pharmacokinetics (PK) absorption, distribution, metabolism, excretion (ADME) and drug-drug interaction (DDI) profile can be modulated by age, disease, and genotype. In order to facilitate subject phenotyping and clinical DDI assessment, therefore, various endogenous compounds (in plasma and urine) have been pursued as drug-metabolizing enzyme and transporter biomarkers. Compared with biomarkers, however, the topic of circulating extracellular vesicles as "liquid biopsy" has received little attention within the ADME community; most organs secrete nanovesicles (e.g., exosomes) into the blood that contain luminal "cargo" derived from the originating organ (proteins, messenger RNA, and microRNA). As such, ADME profiling of plasma exosomes could be leveraged to better define genotype-phenotype relationships and the study of ontogeny, disease, and complex DDIs. If methods to support the isolation of tissue-derived plasma exosomes are successfully developed and validated, it is envisioned that they will be used jointly with genotyping, biomarkers, and modeling tools to greatly progress translational PK-ADME-DDI science.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Rodrigues D, Rowland A. From Endogenous Compounds as Biomarkers to Plasma-Derived Nanovesicles as Liquid Biopsy; Has the Golden Age of Translational Pharmacokinetics-Absorption, Distribution, Metabolism, Excretion-Drug-Drug Interaction Science Finally Arrived? Clin Pharmacol Ther. 2019. PMID: 30554411. doi:10.1002/cpt.1328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。